Genetically manipulated bacterial toxin as a new generation mucosal adjuvant

Scandinavian Journal of Immunology

Volumn 53, Issue 3, 2001, Pages 211-217

  Yamamoto, M ^a,b   Mcghee, J R ^c   Hagiwara, Y ^c   Otake, S ^a   Kiyono, H ^b,c  

^a NIHON UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANTIBODY; ANTIGEN; BACTERIAL TOXIN; CD86 ANTIGEN; CHOLERA TOXIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; INTERLEUKIN 4;

ANIMAL CELL; ANTIBODY BLOOD LEVEL; ANTIGEN ANTIBODY COMPLEX; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ENZYME ACTIVITY; ESCHERICHIA COLI; GENETIC MANIPULATION; HELPER CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ANTIGENS, CD86; BACTERIAL TOXINS; CD4-POSITIVE T-LYMPHOCYTES; CHOLERA TOXIN; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; GENETIC ENGINEERING; HUMANS; IMMUNITY, MUCOSAL; INTERLEUKIN-4; MEMBRANE GLYCOPROTEINS; MICE; MUTATION;

EID: 0035127224     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2001.00883.x     Document Type: Review

References (79)

1. Lymphocyte homing and homeostasis
2. The mucosal immune system: Features of inductive and effector sites to consider in mucosal immunization and vaccine development
3. The mucosal immune system: From fundamental concepts to vaccine development
4. Peyer's patches: Morphologic studies
5. Physiology of the intestinal immune system
6. The gut-associated lymphoid tissues and gastrointestinal immunity
7. Acute undifferentiated human diarrhea in the tropics. I. Alterations in intestinal micrflora
8. An investigation of traveller's diarrhoea
9. Enterotoxigenic Escherichia coli isolated from patients with severe cholera-like disease
10. Cholera toxin genes: Nucleotide sequence, deletion analysis and vaccine development
11. Amino acid sequence homology between cholera toxin and Escherichia coli heat-labile toxin
12. Chemistry of cholera toxin: The subunit structure
13. Crystal structure of a cholera toxin-related heat-labile enterotoxin from E. coli
14. The mechanisms of action of cholera toxin in pigeon erythrocyte lysates
15. Intestinal electrolyte transport and diarrheal disease I
16. Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins LTh-I, LT-IIa, and LT-IIb
17. Rabbit intestinal glycoprotein receptor for Escherichia coli heat-labile enterotoxin lacking affinity for cholera toxin
18. Comparison of receptors for cholera and Escherichia coli enterotoxins in human intestine
19. Oral immunization with the B subunit of the heat-labile enterotoxin of Escherichia coli induces early Th1 and late Th2 cytokine expression in Peyer's patches
20. Structure and function of cholera toxin and the related Escherichia coli heat-labile, enterotoxin
21. Epitope maps of Escherichia coli labile toxin B subunit for development of a synthetic oral vaccine
22. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin
23. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens
24. Cholera toxin and cholera B subuit as oral-mucosal adjuvant and antigen vector systems
25. Helper T cell subsets for immunoglobulin A responses: Oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues
26. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity
27. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A
28. + Th2 cells producing IL-6 and IL-10 are associated with mucosal IgA responses
29. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4
30. Cholera toxin feeding did not induce oral tolerance in mice and abrogates oral tolerance to an unrelated protein antigen
31. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens
32. Cholera holotoxin and its B subunit enhance Peyer's patch B cell responses induced by orally administered influenza virus: Disproportionate cholera toxin enhancement of the IgA B cell response
33. H-2-unrestricted adjuvant effect of cholera toxin B subunit on murine antibody responses to influenza virus haemagglutinin
34. Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response
35. Manipulation of intestinal immune responses against ovalbumin by cholera toxin and its B subunit in mice
36. Oral administration of cholera toxin-Sendai virus conjugate potentiates gut and respiratory immunity against Sendai virus
37. Intestinal mucosal memory and presence of memory cells in lamina propria and Peyer's patches in mice two years after oral immunization with cholera toxin
38. The adjuvant action of cholera toxin is associated with an increased intestinal permeability for luminal antigen
39. Cholera toxin adjuvant promotes long-term immunological memory in the gut mucosa to unrelated immunogens after oral immunization
40. Intraduodenal application of cholera holotoxin increases the potential of clones from Peyer's patch B cells of relevant and unrelated specificities to secrete IgG and IgA
41. Cholera toxin promotes B cell isotype differentiation
42. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro
43. Inhibition of murine lymphocytes proliferation by the B subunit of cholera toxin
44. Cellular basis of immunomodulation by cholera toxin in vitro with possible association to the adjuvant function in vivo
45. Distinct effects of recombinant cholera toxin B subunit and holotoxin on different stages of class 11 MHC antigen processing and presentation by macrophages
46. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues
47. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants
48. Role of receptor binding in toxicity, immunogenicity, and adjuvanticity of Escherichia coli heat-labile enterotoxin
49. Use of heat-labile toxin of enterotoxigenic Escherichia coli to facilitate mucosal immunization
50. LT (R192G), a non-toxic mutant of the heat-labileenterotoxin of Escherichia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp.
51. Levels of expression and immunogenicity of attenuated Salmonella enterica serovar typhimurium strains expressing Escherichia coli mutant heat-labile enterotoxin
52. Native and mutant forms of cholera toxin and heat-labile enterotoxin effectively enhance protective efficacy of live attenuated and heat-killed Shigella vaccines
53. Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine
54. Killed Campylobacter elicits immune response and protection when administered with an oral adjuvant
55. Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after 1g receptor engagement by antigen
56. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse
57. CD28/B7 system of T cell costimulation
58. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy
59. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL
60. + T cells and induce similar patterns of cytokine secretion in vitro
61. Genetically engineered nontoxic vaccine adjuvant that combine B cell targeting with immunomodulation by cholera toxin A, subunit
62. The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective up-regulation of B7.2 expression
63. Enterotoxin adjuvants have direct effects on T cells and antigen-presenting cells that results in either interleukin-4-dependent or -independent immune responses
64. Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant
65. Inhibition of routine T cell activation by cholera toxin B subunit is not mediated through the phosphatidylinositol second messenger system
66. Cholera toxin discriminates between T helper 1 and 2 cells in T cell receptor-mediated activation: Role of cAMP in T cell proliferation
67. Cholera toxin B subunit binding to an antigen-presenting cell directly co-stimulates cytokine production from a T cell clone
68. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity
69. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity
70. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin
71. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity
72. Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli
73. Mutants of the Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin
74. Mutational analysis of the role of ADP-ribosylation activity and GM1-binding activity in the adjuvant properties of the Escherichia coli heat-labile enterotoxin towards intranasally administered keyhole limpet hemocyanin
75. Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit
76. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant
77. Dissociation of Escherichia coli heat-labile toxin adjuvanticity from ADP-ribosyltransferase activity
78. A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit
79. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A